Hansoh Pharmaceutical Group (HKG:3692) said the second biologics license application or BLA of its antibody drug XINYUE (Inebilizumab Injection) was accepted by the National Medical Products Administration or NMPA, a Tuesday bourse filing said.
The drug is a targeted CD19 B cell-depleting antibody and is used to treat immunoglobulin G4-related disease, a chronic inflammatory condition.
In May 2019, Viela Bio granted the group the exclusive license to develop and commercialize the drug in China, Hong Kong, and Macau.
NMPA approved the launch of the drug in China in 2022, while the drug was also included in the national reimbursement drug list in 2023, a status that was renewed in November 2024.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。